1. The Long-Term Outcome of Medical Therapy for BPH
Stephan Madersbacher, Martin Marszalek, Jakob Lackner, Peter Berger, Georg Schatzl 
European Urology 
Volume 51, Issue 6, Pages (June 2007)
DOI: /j.eururo
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
Placebo response in long-term medical trials. The data of all trials listed in Table 1 were analysed; some trials contained no detailed information regarding maximum flow rate (Qmax). Each dot indicates the placebo arm of one study, the horizontal bars the respective mean values.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Impact of long-term medical therapy on lower urinary tract symptoms. All trials listed in Table 1 are included. Light-orange bar=active substance; Dark-orange bar=comparator, with the exception of two plant extract trials (see asterisk) — always placebo.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Impact of long-term medical therapy on maximum flow rate (Qmax). All trials listed in Table 1 are included. Light-orange bar=active substance; Dark-orange bar=comparator, with the exception of two plant extract trials (see asterisk) — always placebo.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Drop-out rates in long-term medical trials. Black=plant extracts; orange=α1-blocker; green=5α-reductase inhibitors; blue=combination therapy.
European Urology  , DOI: ( /j.eururo )
Copyright © 2007 European Association of Urology Terms and Conditions